| Literature DB >> 24886866 |
Hee Jae Shin1, Hwa-Sun Lee2, Jong Seok Lee3, Junho Shin4, Min Ah Lee5, Hyi-Seung Lee2, Yeon-Ju Lee6, Jieun Yun7, Jong Soon Kang8.
Abstract
Two new α-pyrone derivatives, violapyrones H (1) and I (2), along with known violapyrones B (3) and C (4) were isolated from the fermentation broth of a marine actinomycete Streptomyces sp. The strain was derived from a crown-of-thorns starfish, Acanthaster planci, collected from Chuuk, Federated States of Micronesia. The structures of violapyrones were elucidated by the analysis of 1D and 2D NMR and HR-ESIMS data. Violapyrones (1-4) exhibited cytotoxicity against 10 human cancer cell lines with GI50 values of 1.10-26.12 μg/mL when tested using sulforhodamine B (SRB) assay. This is the first report on the cytotoxicity of violapyrones against cancer cell lines and the absolute configuration of violapyrone C.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24886866 PMCID: PMC4071576 DOI: 10.3390/md12063283
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of violapyrones H (1), I (2), B (3) and C (4).
1H and 13C NMR data of 1 and 2 in CD3OD.
| Position | 1 | 2 | ||
|---|---|---|---|---|
| δC, Type | δH, Mult. ( | δC, Type | δH, Mult. ( | |
| 2 | 169.9, C | 169.4, C | ||
| 3 | 98.7, C | 98.9, C | ||
| 4 | 169.5, C | 168.9, C | ||
| 5 | 102.0, CH | 5.96, s | 101.6, CH | 5.97, s |
| 6 | 164.8, C | 164.9, C | ||
| 7 | 34.4, CH2 | 2.46, t (7.5) | 34.4, CH2 | 2.46, t (7.5) |
| 8 | 28.1, CH2 | 1.64, m | 28.1, CH2 | 1.64, m |
| 9 | 30.4, CH2 | 1.34 | 30.3, CH2 | 1.33 |
| 10 | 28.3, CH2 | 1.34 | 30.2, CH2 | 1.35 |
| 11 | 40.1, CH2 | 1.19, m | 33.0, CH2 | 1.30, m |
| 12 | 29.7, CH | 1.53, m | 23.8, CH2 | 1.31, m |
| 13 | 23.1, CH3 (× 2) | 0.88, d (6.5) | 14.5, CH3 | 0.90, t (6.5) |
| 3-Me | 8.4, CH3 | 1.84, s | 8.4, CH3 | 1.85, s |
Figure 2Key HMBC and COSY correlations of 1 in CD3OD.
Growth Inhibition (GI50, μg/mL) of 1–4 against a Panel of Human Tumor Cell Lines.
| Cell Lines | GI50a (μg/mL) | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ADR b | |
| Cervical cancer: HeLa | 25.05 | 5.54 | 18.12 | 9.91 | 0.09 |
| Renal cancer: ACHN | 1.79 | 5.42 | 1.18 | 1.55 | 0.04 |
| Colon cancer: HCT-15 | 1.10 | 3.38 | 2.01 | 5.22 | 0.08 |
| Colon cancer: HCT-116 | 8.99 | 18.08 | 15.83 | 26.12 | 0.09 |
| Breast cancer: MDA-MB-231 | 1.51 | 6.29 | 1.80 | 4.94 | 0.99 |
| Lung cancer: NCI-H23 | 1.24 | 3.47 | 1.90 | 3.24 | 0.04 |
| Lung cancer: NCI-H460 | 4.45 | 21.04 | 6.37 | 10.80 | 0.07 |
| Stomach cancer: NUGC-3 | 1.27 | 3.36 | 2.24 | 4.02 | 0.12 |
| Liver cancer: Hep-G2 | 2.30 | 14.60 | 2.04 | 3.96 | 0.08 |
| Prostate cancer: PC-3 | 1.37 | 5.44 | 1.40 | 2.06 | 0.06 |
a GI50 values are the concentration corresponding to 50% growth inhibition; b ADR: adriamycin as standard.